Eton Pharmaceuticals (ETON): Maybe today then

Play Episode

7min

Proactive - Interviews for investors

Genflow Biosciences CEO welcomes new investment; outlines dog longevity trial

Genflow Biosciences PLC CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about a pivotal new direction for the company as it initiates a clinical trial focused on improving aging in dogs. Leire described the trial as a natural evolution from Genflow's previous success in mice, noting the commercial appeal of the canine market. “There is nothing to improve really the quality of life of our aging dogs,” he said, adding that the study meets a significant unmet need. The trial will run for one year, with six months of treatment followed by six months of assessment. It's being managed by independent contract research organisation Syngene. Leire emphasised the scientific rigour of the trial, which is controlled, randomised and includes both aesthetic and biological endpoints. These include coat quality, mitochondrial function, and methylation clocks — all of which have potential crossover value for human applications. Leire also highlighted the company’s differentiated approach compared to US competitors using repurposed drugs like metformin. Genflow, he said, is pursuing gene therapy with the potential for greater impact. The investment supporting the trial, although limited in size, is seen as a strategic vote of confidence, bringing in credible investors from outside the UK, including the US. Leire described the initiative as a major step that could generate near-term revenue and redefine the company’s biotech positioning. For more company updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future content. #GenflowBiosciences #GeneTherapy #DogAging #BiotechInvestment #LongevityResearch #Mitochondria #PetHealth #ClinicalTrials #AgingDogs #BiotechNews

Proactive - Interviews for investors

AuKing prepares for gold mining at Mt Freda site

AuKing Mining Ltd managing director Paul Williams talked with Proactive about the company's latest update on its Cloncurry Project in Queensland, focusing on the Mt Freda deposit. Williams confirmed that with Orion Resources nearing acquisition completion, AuKing is preparing to restart mining operations at the historical Mt Freda gold mine. Williams highlighted Mt Freda as a top target for redevelopment due to its existing mining lease and approvals, as well as a current resource estimate of around 100,000oz. "We really don't want to start a mining operation unless we've got reserves in the resource estimate," he explained, outlining the company’s aim to confirm and expand those figures through an upcoming drilling program. In addition to resource verification, AuKing is evaluating two processing options: existing vat leaching pits and a nearby cavern in-leach circuit at Lorena. Williams also noted the broader potential in the surrounding six square kilometre Mt Freda Complex, which contains multiple historical deposits, hinting at further exploration upside. Drilling is expected to start within weeks of the acquisition's financial close in April, with results anticipated in the months following. Williams described the program as "a fascinating exercise," indicating renewed momentum behind the restart strategy. For more updates from AuKing Mining Ltd and other resource sector insights, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #AuKingMining #MtFreda #GoldMining #ASXAKN #CloncurryProject #ResourceDrilling #MiningRestart #QueenslandMining #JuniorMining #GoldExploration #MiningInvestment #ASXResources #OrionResources

Proactive - Interviews for investors

Actinogen targets $20B Alzheimer’s market with Xanamem

Actinogen Medical Ltd Managing Director and CEO Dr Stephen Gourlay talked with Proactive at the AIM's Small and Midcap conference about the company’s lead asset, Xanamem, and its development in Alzheimer’s disease and depression. Dr Gourlay explained that Xanamem is an oral, once-a-day drug designed to modulate cortisol levels in the brain without interfering with the body’s essential stress response. “We’ve also shown some positive data, you know, phase two and depression as well, which is very exciting because that validates its mechanism,” he said. He outlined the commercial opportunity in both Alzheimer’s and depression. While depression is more prevalent, the Alzheimer's market offers larger potential revenue. He noted that current treatments either have side effects or provide only temporary cognitive improvement, whereas Xanamem could modify the disease course with a better safety profile. Dr Gourlay discussed Actinogen’s recent momentum, including positive results in a depression trial, a number of peer-reviewed publications, and the upcoming interim analysis from its Alzheimer’s trial in Australia and the US. He said, “The upside from a positive Alzheimer’s trial is completely massive… a multi-billion dollar asset.” The company is currently trading below the total investment into drug development, which Dr Gourlay described as a compelling investment case. #Actinogen #Xanamem #AlzheimersResearch #DepressionTreatment #BiotechStocks #ClinicalTrials #Neuroscience #PharmaInnovation #ASX #ProactiveInvestors

Proactive - Interviews for investors

EnWave expands footprint with commercial license in Japan and U.S. biopharmaceutical agreement

EnWave Corporation CEO Brent Charleton joined Steve Darling from Proactive to announce the company has signed a commercial license agreement with Hokkai Yamato Foods Japan, a leading producer of processed foods such as soups, furikake, and ochazuke. As part of the agreement, Hokkai Yamato has acquired a 10kW Radiant Energy Vacuum (REV™) machine to drive product development and support early-stage commercial production in Japan. This license grants Hokkai Yamato exclusive rights to use EnWave’s patented REV™ technology for the production of various food products within Japan. In return, Hokkai Yamato will pay royalties to EnWave, consistent with existing licensing agreements. EnWave will work closely with Hokkai Yamato to optimize product development and ensure long-term commercial success. In addition to expanding its presence in the Japanese food sector, EnWave has also signed a master service agreement with BioTechnique, a U.S.-based pharmaceutical contract manufacturer. This agreement lays the groundwork for BioTechnique to evaluate EnWave’s REV™ dehydration technology as a potential alternative to freeze-drying in biopharmaceutical applications. As part of the collaboration, BioTechnique will conduct paid testing of several liquid pharmaceutical products, drying them in vials using pilot-scale REV™ machinery at EnWave’s Innovation Center in Delta, British Columbia. If the results prove successful, BioTechnique may choose to acquire its own REV™ equipment to provide dehydration services directly to its network of leading pharmaceutical clients. #proactiveinvestors #enwavecorporation #tsxv #enw #DehydrationTech #VacuumMicrowave #RoyaltyBusinessModel #BluechipClients #FoodTech #BusinessNews #Investing #CEOInterview #Peru #Spain #Blueberry #Snacks #Royalties #TradeMission

Followers	8
Posts	727
Boards Moderated	0
Alias Born	08/26/2018

Volume:	173,499
Day Range:	12.83 - 13.6362
Bid:	11.44
Ask:	16.75
Last Trade Time:	4:09:43 PM EDT
Total Trades:	2,466

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

ETON Detailed Quote

Recent ETON News

More ETON News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent ETON News

Go Ad-Free